Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DB-1311 + DB-1305
- Development stage
- Unknown
- Lead developer
- Duality Biotherapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DB-1311 + DB-1305 is a combination of two investigational antibody-drug conjugates (ADCs) for the treatment of advanced or metastatic solid tumors. DB-1311 is an anti-B7-H3 ADC that utilizes P1021, a topoisomerase I inhibitor, as its cytotoxic payload and targets the B7-H3 protein, which is overexpressed in several cancers and associated with poor prognosis. By targeting B7-H3, DB-1311 aims to deliver the cytotoxic payload specifically to tumor cells[4][6]. DB-1305 is an anti-TROP2 ADC, likely using a similar topoisomerase payload, with the purpose of targeting the TROP2 antigen that is highly expressed in many epithelial tumors[7]. Both drugs are being developed by DualityBio in collaboration with BioNTech, and this combination is currently being tested in clinical trials for patients with difficult-to-treat solid tumors, such as hepatocellular carcinoma, cervical cancer, melanoma, ovarian cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer[1][2][3][5].
- Other names
- BNT324/DB-1311 + DB-1305/BNT325
02
Targets
B7-H3TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on DB-1311 + DB-1305.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DB-1311 + DB-1305.